IDVV Last trade .43. Price Target 2.00.
Ludlow Research Initiates Coverage on IDVV Based on Launch of Biomedical Research Firm
(NEW YORK) – Ludlow Research initiated coverage on International Endeavors Corporation (OTCMKTS: IDVV) based on their launch of biomedical research firm focused on the use of nonpsychoactive cannabis based products, with a ‘speculative’ target of $2.00 per share. The Company announced a joint partnership with Kubby Cryogenics Inc. to launch a biomedical research firm strictly focused on the use of non-psychoactive cannabis based products for the treatment of a wide variety of illnesses.
Under the agreement, Kubby Cryogenics will look to patent medical grade cannabis strains that are genetically profiled to treating specific diseases, such as Cancer, Fibromyalgia, Arthritis, High Blood Pressure, Epilepsy, Brain Injury, Stroke, Inflammation, and PTSD.
The company will be acquiring licensing rights to patent new delivery systems in the future. Further, the company will continue with product development in their own proprietary Cryogenics line, which captures the highest medical value of any product known on the market today.
Non-Psychoactive Medical Research
The main take away for investors looking at this company is that IDVV isn’t going to be your run of the mill marijuana play, but rather a traditional ‘biotech research firm’ that conducts a core of its research on the non-psychoactive use of cannabis using a specialized cryogenic process.
Popular CEO Appointed
Steve Kubby, the new CEO of IDVV, played a key role in the passage of California Proposition 215, a ballot initiative passed in 1996 to legalize medical marijuana. He is a well-known cancer patient of 36 years, who benefits his recovery through the use of non-psychoactive Cryogenics, a raw cannabis extract. Steve Kubby was formally Chairman and CEO of Cannabis Sativa Inc. (OTCMKTS: CBDS), and has authored 2 books on drug policy reform. Mr. Kubby’s distinguished political career includes runs for Governor of California in 1998, and the 2008 Presidential primary race under the libertarian ticket.
Sell Growers, Buy Medical
Ludlow Research recently issued a note to our subscribers regarding investors wanting to invest in the marijuana stocks that they may want to sell the growers, dispensaries, and recreational plays, and focus investment capital more in a diversified basket of companies focused strictly on the medical research side due to potential regulatory risks.
For this reason Ludlow Research has initiated coverage on IDVV based on their new management, strict focus on non-psychoactive cannabis research for the treatment of a wide variety of illnesses, and low public float, with a ‘speculative’ short-term target of around $2.00+ per share.
3
This would place IDVV with similar pure medical marijuana plays such as OWC Pharmaceutical Research Corp (OTC:OWCP) India Globalization Capital, Inc. (NYSE: IGC), 22nd Century Group, Inc. (NYSE:XXII), Freedom Leaf, Inc. (OTC:FRLF), or Medical Marijuana Inc. (OTC:MJNA) to name a few.
About International Endeavors Corporation
International Endeavors Corporation is a company focused on biomedical uses of nonpsychoactive cannabis based products for the treatment of a wide variety of illnesses. Through a unique patent pending Cryogenic process, the Company can process different unique medical grade cannabis strains that are genetically profiled to treating specific diseases. www.internationalendeavorscorp.com
About Ludlow Research
Ludlow Research is a New York based equity research firm that focuses on providing research coverage and investor awareness services to emerging small-cap companies. For over 14 years we have worked to provide our readers with a simple way of evaluating the current and potential value of small-cap companies, while garnering these clients greater market awareness to new investors. For more information on us please visit www.ludlowresearch.com
* Ludlow Research launched coverage on International Endeavors Corporation (OTC:IDVV) on Oct. 10, 2017 at a price of $0.30 per share.
Disclaimer:
This is NOT a solicitation to Buy or Sell any security, but rather is for informational purposes only. Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Ludlow Capital, Inc ("Ludlow"
does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. Ludlow, its affiliates, or directors, may or may not hold a position in the above security from time to time, and investors are encourage to consider this as a possible conflict of interest when reviewing this information. In Compliance with SEC Rule 17B as of the date of this report Ludlow was compensated thirty thousand restricted common shares for ongoing media advisory services, and thus should be considered a possible conflict of interest when reviewing this report and information. Ludlow, or its affiliates, may hold a position in above securities from time to time, and thus should be considered a possible conflict of interest when reviewing this report and information. These investments may involve a high degree of risk, thus investors are highly encouraged to consult with a financial advisor before any and all investments.
Safe Harbor Statements:
This website includes statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
Forward-Looking Statements This news release contains certain statements that may be deemed "forward-looking" statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by law, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.
High Risk Small and Micro cap, or 'penny stocks', involve a high degree of risk, and we highly encourage investors to consult with a financial advisor before making any and all investment decisions when investing in these type of securities.
Ludlow Research Initiates Coverage on IDVV Based on Launch of Biomedical Research Firm
(NEW YORK) – Ludlow Research initiated coverage on International Endeavors Corporation (OTCMKTS: IDVV) based on their launch of biomedical research firm focused on the use of nonpsychoactive cannabis based products, with a ‘speculative’ target of $2.00 per share. The Company announced a joint partnership with Kubby Cryogenics Inc. to launch a biomedical research firm strictly focused on the use of non-psychoactive cannabis based products for the treatment of a wide variety of illnesses.
Under the agreement, Kubby Cryogenics will look to patent medical grade cannabis strains that are genetically profiled to treating specific diseases, such as Cancer, Fibromyalgia, Arthritis, High Blood Pressure, Epilepsy, Brain Injury, Stroke, Inflammation, and PTSD.
The company will be acquiring licensing rights to patent new delivery systems in the future. Further, the company will continue with product development in their own proprietary Cryogenics line, which captures the highest medical value of any product known on the market today.
Non-Psychoactive Medical Research
The main take away for investors looking at this company is that IDVV isn’t going to be your run of the mill marijuana play, but rather a traditional ‘biotech research firm’ that conducts a core of its research on the non-psychoactive use of cannabis using a specialized cryogenic process.
Popular CEO Appointed
Steve Kubby, the new CEO of IDVV, played a key role in the passage of California Proposition 215, a ballot initiative passed in 1996 to legalize medical marijuana. He is a well-known cancer patient of 36 years, who benefits his recovery through the use of non-psychoactive Cryogenics, a raw cannabis extract. Steve Kubby was formally Chairman and CEO of Cannabis Sativa Inc. (OTCMKTS: CBDS), and has authored 2 books on drug policy reform. Mr. Kubby’s distinguished political career includes runs for Governor of California in 1998, and the 2008 Presidential primary race under the libertarian ticket.
Sell Growers, Buy Medical
Ludlow Research recently issued a note to our subscribers regarding investors wanting to invest in the marijuana stocks that they may want to sell the growers, dispensaries, and recreational plays, and focus investment capital more in a diversified basket of companies focused strictly on the medical research side due to potential regulatory risks.
For this reason Ludlow Research has initiated coverage on IDVV based on their new management, strict focus on non-psychoactive cannabis research for the treatment of a wide variety of illnesses, and low public float, with a ‘speculative’ short-term target of around $2.00+ per share.
3
This would place IDVV with similar pure medical marijuana plays such as OWC Pharmaceutical Research Corp (OTC:OWCP) India Globalization Capital, Inc. (NYSE: IGC), 22nd Century Group, Inc. (NYSE:XXII), Freedom Leaf, Inc. (OTC:FRLF), or Medical Marijuana Inc. (OTC:MJNA) to name a few.
About International Endeavors Corporation
International Endeavors Corporation is a company focused on biomedical uses of nonpsychoactive cannabis based products for the treatment of a wide variety of illnesses. Through a unique patent pending Cryogenic process, the Company can process different unique medical grade cannabis strains that are genetically profiled to treating specific diseases. www.internationalendeavorscorp.com
About Ludlow Research
Ludlow Research is a New York based equity research firm that focuses on providing research coverage and investor awareness services to emerging small-cap companies. For over 14 years we have worked to provide our readers with a simple way of evaluating the current and potential value of small-cap companies, while garnering these clients greater market awareness to new investors. For more information on us please visit www.ludlowresearch.com
* Ludlow Research launched coverage on International Endeavors Corporation (OTC:IDVV) on Oct. 10, 2017 at a price of $0.30 per share.
Disclaimer:
This is NOT a solicitation to Buy or Sell any security, but rather is for informational purposes only. Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Ludlow Capital, Inc ("Ludlow"
does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. Ludlow, its affiliates, or directors, may or may not hold a position in the above security from time to time, and investors are encourage to consider this as a possible conflict of interest when reviewing this information. In Compliance with SEC Rule 17B as of the date of this report Ludlow was compensated thirty thousand restricted common shares for ongoing media advisory services, and thus should be considered a possible conflict of interest when reviewing this report and information. Ludlow, or its affiliates, may hold a position in above securities from time to time, and thus should be considered a possible conflict of interest when reviewing this report and information. These investments may involve a high degree of risk, thus investors are highly encouraged to consult with a financial advisor before any and all investments. Safe Harbor Statements:
This website includes statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
Forward-Looking Statements This news release contains certain statements that may be deemed "forward-looking" statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by law, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.
High Risk Small and Micro cap, or 'penny stocks', involve a high degree of risk, and we highly encourage investors to consult with a financial advisor before making any and all investment decisions when investing in these type of securities.
